MEI Pharma : The H.C. Wainwright 23rd Annual Global Investment Conference

On Target:

Developing Best-in-Class Cancer Therapies

H.C. Wainwright 23rd Annual Global Investment Conference

September 13-15, 2021

Forward-Looking Statements

This presentation contains, and our officers and representatives may from time to time make,

statements that are "forward-looking

statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Examples of forward-looking statements include, among others, statements regarding our development strategy; potential advantages of our product candidates; the initiation and completion of preclinical and clinical studies and the reporting of the results thereof; the timing of regulatory submissions and actions; the sufficiency of our existing cash; and all other statements relating to our plans, objectives, expectations and beliefs regarding future performance, operations, financial condition and other future events (including assumptions underlying or relating to any of the foregoing).

These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others: uncertainties relating to the initiation and completion of preclinical and clinical studies; whether preclinical and clinical study results will validate and support the safety and efficacy of our product candidates; the outcome of regulatory reviews of our product candidates; varying interpretation of research and development and market data; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; risks and uncertainties relating to intellectual property and the other factors discussed under the caption "Item 1A. Risk Factors" in our most recent annual report on Form 10-K and our most recent quarterly report on Form 10-Q.

Any forward-looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. In addition, we operate in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statement. You are urged to carefully review and consider the various disclosures in our most recent annual report on Form 10-K, our most recent Form 10-Q and our other public filings with the SEC since the filing of our most recent annual report.

2

MEI Pharma: Dedicated to Developing Best-in-Class Cancer Therapies

Clinical Development Company Building a Leading Oncology Franchise with 4 Clinical-StagePrograms: Focus On HemOnc

Zandelisib, a PI3Kδ Inhibitor with	Well-Capitalized with $153.4
Potential to Set Standard-of-Care	Million*
In Clinical Trials to Support
Marketing Approvals with the U.S.
FDA and Other Regulatory
Authorities Globally

* As of June 30, 2021, MEI had $153.4 million in cash, cash equivalents, and short-term investments with no outstanding debt.

3

Late-Stage Diversified Clinical Pipeline

PROGRAM S	PROPOSED INDICATION	COMBINATION	PHASE 1/1B	PHASE 2	PHASE 3

Zandelisib	Follicular & Marginal Zone
		COASTAL Study
Oral PI3K Delta Inhibitor	Lymphomas	Rituximab
	Relapsed/refractory (2L+)
	Follicular & Marginal Zone
	Monotherapy		TIDAL (FL) Study1
	Lymphomas
		TIDAL (MZL) Study1
	Relapsed/refractory (3L+)
	B-Cell Malignancies	Monotherapy
	Rituxan® (rituximab)
	Relapsed/refractory	Brukinsa2
Commercial Rights:
	Diffuse Large-B-cell	R-CHOP3
	Lymphoma (1L)
Voruciclib	B-Cell Malignancies &	Monotherapy
Oral CDK9 Inhibitor
AML
	Venclexta® (venetoclax)4
Commercial Rights:	Relapsed/refractory
ME-344
Mitochondrial Inhibitor	Solid Tumors	®	3
	Avastin (bevacizumab)
Commercial Rights:

Pracinostat	Myelodysplastic
HDAC Inhibitor
Syndrome	Vidaza® (azacitidine)
Commercial Rights:	Treatment-naïve

1.	Phase 2 study intended to support accelerated approval marketing applications with FDA. 2. Study arm initiated under clinical collaboration with BeiGene, Ltd.
3.	Investigator-initiated trial. 4. Initiation of clinical studies is subject to opening of a new Investigational New Drug Application with FDA	4

Zandelisib: Data Driven

Advancement in B-cell

Malignancies